Journal: Scientific Reports

Article Title: MicroRNA-205-5p inhibits skin cancer cell proliferation and increase drug sensitivity by targeting TNFAIP8

doi: 10.1038/s41598-021-85097-6

Figure Lengend Snippet: TNFAIP8 expression is upregulated in BCC, SCC, and melanoma patient skin tissues. ( A ) Relative immunohistochemical TNFAIP8 expression in indicated skin cancer tissues is presented. ( B ) Immunohistochemical expression levels of TNFAIP8 protein from normal skin (n = 6), BCC (n = 6), H-SCC (n = 4), M-SCC (n = 4), L-SCC (n = 4), nevus (n = 6), and melanoma (n = 6) tissues were quantified using ImageJ software ( https://imagej.nih.gov/ij/ ) and plotted. The data represent mean ± SEM from 4 to 6 skin cancer tissues. * P < 0.05 relative to normal skin tissues. ( C ) Expression of TNFAIP8 transcripts between cutaneous melanoma (n = 45) and melanoma precursor (n = 18) samples were analyzed and presented from the Oncomine dataset ( https://www.oncomine.org/resource/login.html accessed October 17, 2020). *** P < 0.001 relatives to cutaneous melanoma tissues. ( D , E ) Expression of wild-type B-RAF, mutant B-RAF V600E , and TNFAIP8 in HaCaT, SK-MEL-2, A431, A375, and A2058 cells were analyzed by western blotting. Fifty micrograms of lysates from normal and skin cancer cells were immunoblotted with B-RAF, TNFAIP8, GAPDH, and β-actin antibodies. Immunoreactive bands were visualized using ECL chemiluminescence detection reagents after exposing the blots on X-ray films ( D ) or by scanning the blots with an Odyssey CLx Imager ( E ). The immunoblot scans were converted into grayscale and presented. ( F ) Expression of TNFAIP8 mRNA from indicated normal skin cells and skin cancer cells were analyzed by RT/qPCR as described in the “ ” section.

Article Snippet: Anti-β-actin antibody from Sigma (St. Louis, MO) and anti-TNFAIP8 antibody from Proteintech Group (Rosemont, IL) was also purchased.

Techniques: Expressing, Immunohistochemical staining, Software, Mutagenesis, Western Blot, Quantitative RT-PCR

Journal: Scientific Reports

Article Title: MicroRNA-205-5p inhibits skin cancer cell proliferation and increase drug sensitivity by targeting TNFAIP8

doi: 10.1038/s41598-021-85097-6

Figure Lengend Snippet: TNFα-induced TNFAIP8 expression in skin cancer cells ( A ) Schematic represents TNFAIP8 isoform-specific forward and reverse primer design. ( B ) The expression of different variants/isoforms of TNFAIP8 in normal HaCaT and skin cancer cells was analyzed by RT-PCR. NC–negative control (no cDNA). ( C ) HaCaT, A431, A375, and A2058 cells were treated with vehicle or TNFα (10–50 ng/ml) for 30 h, and cell lysates were immunoblotted with TNFAIP8 or β-actin antibodies. Immunoreactive bands were visualized using ECL chemiluminescence detection reagents and the blots were scanned using an Odyssey CLx imager. The immunoblot scans were converted into grayscale and presented. ( D ) Similarly, normal and skin cancer cells were treated with vehicle or TNFα (10-50 ng/ml) for 30 h, and TNFAIP8 mRNA expression was analyzed by RT/qPCR as described in the “ ” section. * P < 0.05, ** P < 0.01, *** P < 0.001 relative to control/vehicle-treated cells. ( E ) HaCaT, A431, A375 and, A2058 cells were treated with vehicle or TNFα (10–50 ng/ml) for 48 h and, relative cell survival was analyzed by MTT assay as described in the “ ” section. Results are representative of three independent experiments. * P < 0.05, *** P < 0.001 relative to control/vehicle-treated cells.

Article Snippet: Anti-β-actin antibody from Sigma (St. Louis, MO) and anti-TNFAIP8 antibody from Proteintech Group (Rosemont, IL) was also purchased.

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Negative Control, Western Blot, Quantitative RT-PCR, Control, MTT Assay

Journal: Scientific Reports

Article Title: MicroRNA-205-5p inhibits skin cancer cell proliferation and increase drug sensitivity by targeting TNFAIP8

doi: 10.1038/s41598-021-85097-6

Figure Lengend Snippet: TNFAIP8 regulates cell proliferation and migration in skin cancer cells. ( A ) Western blotting analysis of TNFAIP8-Myc tagged protein expression in HaCaT and skin cancer cells. Immunoreactive bands were developed using ECL chemiluminescence detection reagents and the blots were scanned using an Odyssey CLx imager. The immunoblot scans were converted into grayscale and presented. (B) Effect of TNFAIP8-Myc protein overexpression on HaCaT, A431, A375 and, A2058 on cell survival was measured by MTT assay. Results are representative of three independent experiments. * P < 0.05 relative to EV transfected cells. ( C ) The effect of overexpression of TNFAIP8-Myc on cell colony formation was analyzed and plotted (upper and lower panels) as described in the “ ” section. * P < 0.05 relative to EV transfected cells. ( D ) HaCaT, A431, A375 and, A2058 cells were transfected with control siRNA or TNFAIP8 siRNA (100 nM) for 30 h, and cell lysates were western blotted with anti-TNFAIP8 and β-actin antibodies. Western blots were developed using ECL chemiluminescence detection reagents and the blots were scanned using an Odyssey CLx imager. The immunoblot scans were converted into grayscale and presented. TNFAIP8 and β-actin protein levels were quantified using ImageJ software ( https://imagej.nih.gov/ij/ ) and presented below. ( E ) The effect of TNFAIP8 knockdown by siRNA on cell survival was analyzed by MTT assay. The experiments were independently performed three times. * P < 0.05 relative to control siRNA transfected cells. ( F ) Control siRNA and TNFAIP8 siRNA-transfected HaCaT, A431, A375 and A2058 cells (3000 cells/well) were re-plated in 6-well plates in triplicate for 7–10 days and skin cancer cell colony formation was analyzed and plotted (upper and lower panels) as described in the “ ” section. * P < 0.05 relative to control siRNA transfected cells. ( G ) Wound healing assay: HaCaT, A431, A375 and A2058 cells were transfected with control siRNA or TNFAIP8 siRNA for 48 h. The effect of the TNFAIP8 knockdown on cell migration was analyzed using the wound healing assay. Representative images of the wound healing assay (top) and the calculated scratch area (bottom) are shown. * P < 0.05 relative to control siRNA transfected cells.

Article Snippet: Anti-β-actin antibody from Sigma (St. Louis, MO) and anti-TNFAIP8 antibody from Proteintech Group (Rosemont, IL) was also purchased.

Techniques: Migration, Western Blot, Expressing, Over Expression, MTT Assay, Transfection, Control, Software, Knockdown, Wound Healing Assay

Journal: Scientific Reports

Article Title: MicroRNA-205-5p inhibits skin cancer cell proliferation and increase drug sensitivity by targeting TNFAIP8

doi: 10.1038/s41598-021-85097-6

Figure Lengend Snippet: miR-205-5p targets the 3′UTR of TNFAIP8 and inhibits TNFAIP8 expression. ( A ) The binding site of miR-205-5p in the 3′UTR of TNFAIP8 was analyzed by TargetScan ( http://www.targetscan.org/vert_72/ ) and presented. We also generated a wild type and mutated binding nucleotides of miR-205-5p to the 3′UTR of TNFAIP8. Wild-type miR-205-5p and mutant miR-205-5p mimics are shown. ( B ) Relative expression of miR-205-5p in HaCaT, A431, A375, A2058, and SK-MEL-2 cell lines was analyzed by RT/qPCR as described in the “ ” section. ( C ) Luciferase reporter assay: A431 and A2058 cells were transfected with TNFAIP8-3′UTR-Luciferase reporter construct (0.5 µg) for 18 h and then transfected with NC mimic or wild-type miR-205-5p mimic or mutant miR-205-5p mimic for an additional 24 h. Transfected cells were lysed, and luciferase activity was measured. Results are representative of two independent experiments. ** P < 0.01, *** P < 0.001 compared with NC or mutant-type miR-205-5p mimic. ( D , E ) Normal or skin cancer cells were transfected with NC or miR-205-5p mimic for 48 h and the overexpression of miR-205-5p mimic and TNFAIP8 transcripts were analyzed by RT/qPCR. *** P < 0.001 compared with NC-transfected cells. * P < 0.05 compared with NC-transfected cells. ns-no significance. ( F ) HaCaT, A431 and A2058 cell lines were transfected with NC mimic or miR-205-5p mimic for 40 h and expression of endogenous TNFAIP8 protein were analyzed by western blotting. Western blots were developed using ECL chemiluminescence detection reagents, the blots were exposed to X-Ray films, scans were converted into grayscale and presented. ( G ) HaCaT, 431 and A2058 cell lines were grown on a coverslip and transfected with Cy3-labeled NC mimic or Cy3-labeled miR-205-5p mimic and the effect of Cy3-labeled miR-205-5p mimic on endogenous TNFAIP8 expression (green) was visualized by immunofluorescence as described in the “ ” section.

Article Snippet: Anti-β-actin antibody from Sigma (St. Louis, MO) and anti-TNFAIP8 antibody from Proteintech Group (Rosemont, IL) was also purchased.

Techniques: Expressing, Binding Assay, Generated, Mutagenesis, Quantitative RT-PCR, Luciferase, Reporter Assay, Transfection, Construct, Activity Assay, Over Expression, Western Blot, Labeling, Immunofluorescence

Journal: Scientific Reports

Article Title: MicroRNA-205-5p inhibits skin cancer cell proliferation and increase drug sensitivity by targeting TNFAIP8

doi: 10.1038/s41598-021-85097-6

Figure Lengend Snippet: miR-205-5p targets TNFAIP8 and reduces TNFAIP8-mediated cell proliferation and autophagy. ( A ) HaCaT, A431 and A2058 cells were transfected with NC mimic or miR-205-5p mimic for 48 h and relative cell survival was analyzed by MTT assay. The experiments were independently repeated three times. * P < 0.05 compared with NC mimic transfected cells. ( B ) NC mimic or miR-205-5p mimic transfected cells were re-plated in 6-well plates for 7–10 days and cell colony formation was analyzed and plotted (upper and lower panels) as described in the “ ” section. The experiment was repeated twice in triplicates. * P < 0.05 relative to NC mimic transfected cells. ( C ) HaCaT, A431 and A2058 cells were transfected EV or TNFAIP8-Myc plasmids for 30 h and lysates were western blotted with anti-Myc, anti-LC3β I/II, and anti-β-actin antibodies. Western blots were developed using ECL chemiluminescence detection reagents, the blots were exposed on X-ray films, converted into grayscale, and presented. ( D ) HaCaT, lanoma A431 and A2058 cells were transfected NC mimic or miR-205-5p mimic for 30 h and lysates were western blotted with anti-TNFAIP8, anti-LC3β I/II, anti-p62, and anti-β-actin antibodies. Western blots were developed using ECL chemiluminescence detection reagents, exposed on X-Ray films, converted into grayscale, and presented. ( E ) HaCaT, A431 and A2058 cells were grown on a coverslip transfected with Cy3-labeled NC mimic or Cy3-labeled miR-205-5p mimic and the effect of Cy3-labeled miR-205-5p mimic on endogenous LC3β I/II expression (green) and related puncta formation were visualized by immunofluorescence (upper panels) as described in the “ ” section (upper panel). LC3β I/II and related puncta were measured from individual cells (n = 10) and plotted (lower panels). ** P < 0.01, *** P < 0.001 relatives to Cy3 labeled-NC mimic transfected cells.

Article Snippet: Anti-β-actin antibody from Sigma (St. Louis, MO) and anti-TNFAIP8 antibody from Proteintech Group (Rosemont, IL) was also purchased.

Techniques: Transfection, MTT Assay, Western Blot, Labeling, Expressing, Immunofluorescence

Journal: Scientific Reports

Article Title: MicroRNA-205-5p inhibits skin cancer cell proliferation and increase drug sensitivity by targeting TNFAIP8

doi: 10.1038/s41598-021-85097-6

Figure Lengend Snippet: miR-205-5p targets TNFAIP8 in skin cancer cells and increase sensitivity to vemurafenib. ( A ) HaCaT cells, and skin cancer SK-MEL-2, A375 and A2058 cell lines were treated with increasing concentrations of vemurafenib for 48 h and relative cell survival/proliferation was measured by MTT assay. The experiments were independently repeated three times. ** P < 0.01, *** P < 0.001 compared to vehicle-treated cells. ( B ) HaCaT cells and skin cancer SK-MEL-2, A375 and A2058 cell lines were transfected with NC mimic or miR-205-5p mimic for 24 h and treated with vemurafenib or vehicle for an additional 48 h and relative cell survival were measured by MTT assay as described in the “ ” section. * P < 0.05, ** P < 0.01, *** P < 0.001 compared to NC mimic vehicle-treated cells or NC mimic and vemurafenib-treated cells. ns-no significance. ( C ) Melanoma A375 cells were transfected with NC mimic or miR-205-5p mimic for 18 h and then cells were treated with vemurafenib for an additional 24 h. Fifty micrograms of lysates were immunoblotted with anti-cleaved-PARP and anti-β-tubulin antibodies. Western blots were developed using ECL chemiluminescence detection reagents, the blots were scanned using Azure C-500 Biosystem, scans were converted into grayscale and presented. ( D ) Melanoma A375 cells were transfected with EV of TNFAIP8-Myc plasmid for 18 h first and then cells were treated with vemurafenib or paclitaxel for 24 h as indicated and fifty micrograms lysates were immunoblotted with anti-Myc, anti-cleaved-PARP, and anti-β-actin antibodies. Western blots were developed using ECL chemiluminescence detection reagents and the blots were scanned using an Odyssey CLx imager. The immunoblot scans were converted into grayscale and presented. ( E ) Fifty micrograms of lysates from A375 and A2058 cells or A375R and A2058R (vemurafenib resistant) cells were immunoblotted with anti-TNFAIP8, anti-LC3β I/II, and anti-β-actin antibodies. Western blots were developed using ECL chemiluminescence detection reagents, the blots were exposed on X-Ray films, scans were converted into grayscale and presented. ( F ) Relative cell proliferation/cell survival rate of A375 and A2058 cells, or A375R and A2058R (vemurafenib resistant) cells were measured by using WST-1 reagent (Cayman Chemical) (upper panel) or MTT assay reagent (lower panel) and plotted. ** P < 0.01, *** P < 0.001 compared to A375 and A2058 parent cells. Results are representative of three independent experiments. Vem. Vemurafenib.

Article Snippet: Anti-β-actin antibody from Sigma (St. Louis, MO) and anti-TNFAIP8 antibody from Proteintech Group (Rosemont, IL) was also purchased.

Techniques: MTT Assay, Transfection, Western Blot, Plasmid Preparation

Journal: Nucleic Acids Research

Article Title: COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics

doi: 10.1093/nar/gkaa969

Figure Lengend Snippet: COVID19-specific collections and chemical libraries

Article Snippet: MedChemExpress , SARS-CoV List of Drugs , 76 , https://www.medchemexpress.com/Targets/SARS-CoV.html.

Techniques: Protein-Protein interactions, Drug discovery

Journal: Communications Biology

Article Title: Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronaviruses

doi: 10.1038/s42003-025-09474-x

Figure Lengend Snippet: Spike-specific IgG titre against SARS-CoV-2, OC43, HKU1, NL63 and 229E in SARS-CoV-2-seronegative unvaccinated donors ( a , n = 124), SARS-CoV-2-seropositive unvaccinated donors ( b , n = 152), SARS-CoV-2-seronegative vaccinated donors ( c , n = 24) and SARS-CoV-2-seropositive vaccinated donors ( d , n = 69). Kruskal–Wallis (Dunn’s multiple comparisons test). Black lines indicate median titre and interquartile range, dotted black line indicates the cutoff. Correlation of age with Spike-specific IgG titre against SARS-CoV-2 (black), OC43 (blue) and HKU1 (green) in seronegative unvaccinated donors ( e , n = 124), seropositive unvaccinated donors ( f , n = 152), seronegative vaccinated donors ( g , n = 24) and seropositive vaccinated donors ( h , n = 69). The Spearman correlation coefficient ( r ) and P -values are shown. Fitted lines are linear regressions. No age-related correlations were observed with HCoVs (Supplementary Fig. ). i Fold change in median SARS-CoV-2 spike IgG titre in seropositive unvaccinated (light red), seronegative vaccinated (black) and seropositive vaccinated (red) donors in relation to seronegative unvaccinated donors. Fold changes are listed. j Fold change in median OC43, HKU1, NL63 and 229E spike-specific IgG in seropositive unvaccinated (light red), seronegative vaccinated (black) and seropositive vaccinated (red) donors in relation to seronegative unvaccinated donors (grey). Fold changes are listed, black dotted line denotes a fold change of 1. Source data: Supplementary Data .

Article Snippet: Donor plasma was diluted 1:10 in PBS prior to incubation at 37 °C for 30 min with an equal volume of either recombinant SARS-CoV-2 S1 protein (R&D Systems, 10569-CV-100) or recombinant SARS-CoV-2 S2 protein (R&D Systems, 10594-CV-100) at a concentration of 500 μg/ml in PBS, or with PBS alone.

Techniques:

Journal: Communications Biology

Article Title: Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronaviruses

doi: 10.1038/s42003-025-09474-x

Figure Lengend Snippet: Correlation of SARS-CoV-2 spike IgG titre with alphacoronavirus spike (NL63 (green) and 229E (yellow), a – d ) and betacoronavirus spike (OC43 (purple) and HKU1 (pink), e – h ) IgG titres in seronegative unvaccinated donors ( a , n = 124), SARS-CoV-2-seropositive unvaccinated donors ( b , n = 152), SARS-CoV-2-seronegative vaccinated donors ( c , n = 24) and SARS-CoV-2-seropositive vaccinated donors ( d n = 69). The Spearman correlation coefficient ( r ) and P -values are shown. Source data: Supplementary Data .

Article Snippet: Donor plasma was diluted 1:10 in PBS prior to incubation at 37 °C for 30 min with an equal volume of either recombinant SARS-CoV-2 S1 protein (R&D Systems, 10569-CV-100) or recombinant SARS-CoV-2 S2 protein (R&D Systems, 10594-CV-100) at a concentration of 500 μg/ml in PBS, or with PBS alone.

Techniques:

Journal: Communications Biology

Article Title: Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronaviruses

doi: 10.1038/s42003-025-09474-x

Figure Lengend Snippet: SARS-CoV-2 ( a ), OC43 ( b ), HKU1 ( c ), NL63 ( d ) and 229E ( e ) spike-specific IgG binding from unvaccinated (pink, n = 18) or vaccinated (orange, n = 23) SARS-CoV-2-seropositive donors following pre-adsorption with either S1 or S2 domains from SARS-CoV-2 Spike protein. Data are expressed as a percentage compared to binding within the unadsorbed control (Control). Friedman test with Dunn’s multiple comparison test was used. Source data: Supplementary Data .

Article Snippet: Donor plasma was diluted 1:10 in PBS prior to incubation at 37 °C for 30 min with an equal volume of either recombinant SARS-CoV-2 S1 protein (R&D Systems, 10569-CV-100) or recombinant SARS-CoV-2 S2 protein (R&D Systems, 10594-CV-100) at a concentration of 500 μg/ml in PBS, or with PBS alone.

Techniques: Binding Assay, Adsorption, Control, Comparison

Journal: Communications Biology

Article Title: Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronaviruses

doi: 10.1038/s42003-025-09474-x

Figure Lengend Snippet: a IFNγ FluoroSpot response to SARS-CoV-2 and HCoV S1 peptide stimulation ( n = 66–87). Kruskal–Wallis (Dunn’s multiple comparisons test). Black lines indicate the median and interquartile range. b IFNγ FluoroSpot response to SARS-CoV-2 and HCoV S2 peptide stimulation ( n = 64–86). Kruskal–Wallis (Dunn’s multiple comparisons test). Black lines indicate the median and interquartile range. c Ratio of S2-specific to S1-specific IFNγ cellular responses in SARS-CoV-2 and HCoV ( n = 54–84). Betacoronaviruses are indicated with purple dots, and alphacoronaviruses are indicated with blue dots. Kruskal–Wallis (Dunn’s multiple comparisons test). Black lines indicate the median and interquartile range. d Ratio of S2-specific to S1-specific IFNγ cellular responses to SARS-CoV-2 (black dots, n = 84), alphacoronaviruses NL63 and 229E (blue dots, n = 66) and betacoronaviruses OC43 and HKU1 (purple dots, n = 74) in relation to age. Dotted black line indicates a S2:S1 ratio of 1. The Spearman correlation coefficient and P -values are shown. Fitted lines are linear regressions. Source data: Supplementary Data .

Article Snippet: Donor plasma was diluted 1:10 in PBS prior to incubation at 37 °C for 30 min with an equal volume of either recombinant SARS-CoV-2 S1 protein (R&D Systems, 10569-CV-100) or recombinant SARS-CoV-2 S2 protein (R&D Systems, 10594-CV-100) at a concentration of 500 μg/ml in PBS, or with PBS alone.

Techniques:

Journal: Communications Biology

Article Title: Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronaviruses

doi: 10.1038/s42003-025-09474-x

Figure Lengend Snippet: a Mean fluorescence intensity (MFI) of CXCL8 within FluoroSpot eluates after stimulation with either S1 or S2 spike peptides from SARS-CoV-2 or OC43 and HKU1 compared to DMSO control. Donors were SARS-CoV-2 vaccinated donors and >65 years of age ( n = 15). Kruskal–Wallis (uncorrected Dunn’s test). Black lines indicate the median MFI with interquartile range. b Mean fluorescence intensity (MFI) of CXCL10, TNFɑ, IFN-ɑ2, IL-7 and IL-10 within FluoroSpot eluates after stimulation with SARS-CoV-2 S1 or S2 peptides compared to a DMSO control in vaccinated donors over the age of 65 ( n = 15). Kruskal–Wallis (uncorrected Dunn’s test). Black lines indicate the median MFI with interquartile range. Source data: Supplementary Data .

Article Snippet: Donor plasma was diluted 1:10 in PBS prior to incubation at 37 °C for 30 min with an equal volume of either recombinant SARS-CoV-2 S1 protein (R&D Systems, 10569-CV-100) or recombinant SARS-CoV-2 S2 protein (R&D Systems, 10594-CV-100) at a concentration of 500 μg/ml in PBS, or with PBS alone.

Techniques: Fluorescence, Control

Journal: bioRxiv

Article Title: Nucleolar stress caused by arginine-rich peptides triggers a ribosomopathy and accelerates ageing in mice

doi: 10.1101/2023.08.10.552792

Figure Lengend Snippet: (A) IF of (PR) 97 HA (red) and FBL (green), in liver sections from littermate PR +/+ and PR KI/KI mice, 3 weeks after treatment with dox in the drinking water. Scale bar (white) represents 10 μm. (B) Quantification of nucleolar FBL+ area from the images shown in (A). (C) GSEA enrichment plots for the “cytoplasmic r-proteins” class from RNA-seq data comparing liver RNA from PR +/+ and PR KI/+ littermates after 17 weeks of treatment with dox. (D) Normalised read counts of all detected r-protein mRNAs, quantified by RNA-seq in total RNA of livers from non-inducible (grey, PR +/+ ) and inducible (blue, PR KI/+ ) littermates, after 17 weeks of treatment with dox. (E) WB evaluating the levels of mTOR signalling (pRPS6), and of total RPS6 and RPS2 levels in livers from non-inducible PR +/+ and inducible PR KI/+ littermates after 20 weeks of treatment with dox. (F) RPS6 and pRPS6 IHC in liver sections from a non-inducible mouse (PR +/+ ) and an inducible littermate (PR KI/KI ), after 3 weeks of treatment with dox. (F) Diagram illustrating the experimental pipeline for the treatment of PR +/+ and PR KI/KI animals with rapamycin and dox. (G) Kaplan-Meyer representation of the lifespan of non-inducible PR +/+ ( n = 13), and inducible PR KI/KI ( n = 13) littermates. Animals started treatment with rapamycin in their diet at week 9, and the treatment with dox started on the following week. Note that rapamycin extends the median lifespan by 60% in inducible mice. (** P < 0.01; Mantel-Cox test). Data information: P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.005; **** P < 0.0001; t -test.

Article Snippet: The following primary antibodies were used: RPS6 (Cell Signaling 2217), p-RPS6 (Cell Signaling, 2215), HA-tag (Roche, 11867423001), p53 (Santa Cruz sc-126), actin (Sigma, A5441), S6K1 (Cell Signalling, 2708), p-S6K1 (Cell Signalling, 2215), TIF1A (Santa Cruz, sc-271266) and RPS2 (Santa Cruz, sc-130399).

Techniques: RNA Sequencing